A d o p T r a c e l l
Speeding CAR Evolution Under the Radar
In the Press
Making Headlines
Researchers demonstrate the feasibility of pancreatic beta-cell, target-specific CAR-Treg treatment for human T1D
June 13, 2022
At the National Meeting of the Endocrine Society, a press release announced: "Researchers have successfully treated type 1 diabetes in mice using pancreatic beta-cell, target-specific, chimeric antigen-receptor (CAR) regulatory T cells (Tregs), and demonstrated the feasibility of their approach to treat the human condition"
AdopTracell Wins iCorps Award
March 15, 2021
Team AdopTracell wins first grant (Alexa Jaume, Entrepreneurial Lead) for CAR Treg commercialization path.
The FDA Investigational New Drug filing process officially begins.
February 12, 2019
University of Toledo (formerly Medical College of Ohio) researchers have generated a mouse that mimics the human development and progression of type 1 diabetes, a breakthrough that will open the door to new therapies.
AdopTracell and the University of Toledo Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Type 1 Diabetes
November 7, 2022
Technology and Patent rights for international WO2020097546 patent entitled " Immunosuppresive Antigen-Specific Chimeric Antigen Receptor Treg Cells for Prevention and/or Treatment of Autoimmune [Type 1 Diabetes and others] and Alloimmune [Solid Organ Transpant] Disorders" belong now to AdopTracell, INC.
AdopTracell Granted Technology Validation Start-up Funding (TVSF Phase II)
February 1, 2022
The Ohio Department of Development has awarded AdopTracell with Technology Validation Start-up Funds (TVSF Phase II, Juan Jaume, PI) for the company to fully develop its patent protected CAR-Treg immune-therapy for Type 1 Diabetes. These grants (Phase I, proof-of-concept; Phase II, validation) are awarded to young companies that have licensed innovative technologies from research institutions.
Reversal of Autoimmunity with Engineered Adoptive Cell Transfer
May 14, 2020
Our technology becomes public. The news of the discovery of immunosuppresive, antigen-specific CAR Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders is now patented!
